PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.
- 7 June 2014
- journal article
- review article
- Vol. 4 (4) , 365-84
Abstract
Hypoxia is a pathological condition arising in living tissues when oxygen supply does not adequately cover the cellular metabolic demand. Detection of this phenomenon in tumors is of the utmost clinical relevance because tumor aggressiveness, metastatic spread, failure to achieve tumor control, increased rate of recurrence, and ultimate poor outcome are all associated with hypoxia. Consequently, in recent decades there has been increasing interest in developing methods for measurement of oxygen levels in tumors. Among the image-based modalities for hypoxia assessment, positron emission tomography (PET) is one of the most extensively investigated based on the various advantages it offers, i.e., broad range of radiopharmaceuticals, good intrinsic resolution, three-dimensional tumor representation, possibility of semiquantification/quantification of the amount of hypoxic tumor burden, overall patient friendliness, and ease of repetition. Compared with the other non-invasive techniques, the biggest advantage of PET imaging is that it offers the highest specificity for detection of hypoxic tissue. Starting with the 2-nitroimidazole family of compounds in the early 1980s, a great number of PET tracers have been developed for the identification of hypoxia in living tissue and solid tumors. This paper provides an overview of the principal PET tracers applied in cancer imaging of hypoxia and discusses in detail their advantages and pitfalls.Keywords
This publication has 141 references indexed in Scilit:
- Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck CancerJournal of Nuclear Medicine, 2009
- Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical ResearchCancer Biotherapy and Radiopharmaceuticals, 2009
- Molecular imaging of hypoxia with radiolabelled agentsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- PET Imaging of HypoxiaPET Clinics, 2009
- Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor modelsRadiotherapy and Oncology, 2008
- FDG uptake, a surrogate of tumour hypoxia?European Journal of Nuclear Medicine and Molecular Imaging, 2008
- Reproducibility of Intratumor Distribution of 18F-Fluoromisonidazole in Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohortEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007